TD Asset Management’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
TD Asset Management's TRDA Position: Q3 2026 in Review
TD Asset Management sold out of Entrada Therapeutics (TRDA) in Q3 2026, closing a stake of 53,588 shares — an estimated $394K sold.
TD Asset Management first reported a position in TRDA in Q4 2021 and held it in 19 quarters. The position peaked at $1.88M in Q3 2023. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- TD Asset Management reported no remaining Entrada Therapeutics position as of Q3 2026 after selling out during the quarter.
- TD Asset Management sold 53,588 Entrada Therapeutics shares in Q3 2026, an estimated $394K.
- TD Asset Management first reported a position in Entrada Therapeutics in Q4 2021 and held it in 19 quarters.
- TD Asset Management's Entrada Therapeutics position peaked at $1.88M in Q3 2023.
- 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on TD Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.